ClinicalTrials.gg
RecruitingNCT06793072Updated Mar 18, 2026

Adipokines in Polycystic Ovary Syndrome

An observational study in PCOS and Reproductive Age, sponsored by Jagiellonian University. Recruiting at 1 site in Poland. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Jagiellonian University · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Insulin Resistance with a site in Poland — 4 open to participants now, 4 under way, none of them phase 3. Insulin Resistance · Poland.

Started
2025
with 4 others
Observational
6 of 27
4 open now
Registered
21st of 27
by date
Lead sponsor
3 of 27
Jagiellonian University

Among the 27 studies in Insulin Resistance with a site in Poland, this one is one of 5 that started in 2025, is one of 6 observational ones, and was the 21st registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

4 of the 27 studies in Insulin Resistance with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Insulin Resistance with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study is to compare the concentrations of leptin, resistin, and omentin-1 in women across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome.

Read the detailed description

Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among reproductive-age women, characterized primarily by insulin resistance (IR), which has a prevalence of 35% to 80%. Metabolic disturbances associated with PCOS contribute to a higher incidence of cardiovascular diseases and endometrial cancer prior to menopause. The hyperinsulinemic-euglycemic clamp study is regarded as the gold standard for assessing insulin sensitivity; however, its clinical application is limited. Alternative assessments, such as the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and fasting insulin or glucose tolerance tests, provide limited clinical utility. Therefore, there is a pressing need for the identification of more precise and universal markers of insulin resistance. There is a need to elucidate the precise role of adipokines in the etiology of PCOS and their association with insulin resistance, which is responsible for the development of adverse health-related complications.

The aim of the study is to measure and compare the concentrations of selected adipokines: leptin, resistin, omentin-1 across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome.

The tests will be performed using immunoenzymatic methods (ELISA) and the Erba XL biochemical analyzer.

The concentrations of the investigated substances will be measured and compared within the three research groups.

Statistical analysis will be conducted using SPSS Statistics software.

03

Conditions studied

  • PCOS
  • Reproductive Age

Keywords

  • insulin resistance
  • polycystic ovary syndrome
  • metabolic syndrome
  • adipokines
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

women aged 18-45 years managed for menstrual irregularities or routine check-up

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-45

Exclusion criteria

Exclusion Criteria:

  • previous removal of at least one ovary
  • treated diabetes of any type
  • diagnosed and treated metabolic diseases
  • diagnosed and treated diseases
  • diagnosed and treated autoinflammatory diseases(Edited)Restore original
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • PCOS+IR

    Polycystic ovary syndrome + insulin resistance

    Diagnostic Test: Leptin concentration in blood serum · Diagnostic Test: Resistin concentration in blood serum · Diagnostic Test: Omentin-1 concentration in blood serum

  • PCOS + no IR

    Polycystic ovary syndrome + no insulin resistance

    Diagnostic Test: Leptin concentration in blood serum · Diagnostic Test: Resistin concentration in blood serum · Diagnostic Test: Omentin-1 concentration in blood serum

  • No PCOS

    Women without PCOS (control)

    Diagnostic Test: Leptin concentration in blood serum · Diagnostic Test: Resistin concentration in blood serum · Diagnostic Test: Omentin-1 concentration in blood serum

Interventions

  • Diagnostic testLeptin concentration in blood serum

    Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms

  • Diagnostic testResistin concentration in blood serum

    Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms

  • Diagnostic testOmentin-1 concentration in blood serum

    Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms

06

What researchers measure

Primary outcomes

  1. Comparison of resistin concentration in three study groups

    Measurement and comparison of mean fasting plasma resistin concentration expressed in pg/ml in three study groups

    Time frame: up to 6 months

  2. Comparison of leptin concentration three study groups

    Measurement and comparison of mean fasting plasma leptin concentration expressed in pg/ml in three study groups

    Time frame: up to 6 months

  3. Comparison of omentin-1 concentration in three study groups

    Measurement and comparison of mean fasting plasma omentin-1 concentration expressed in pg/ml in three study groups

    Time frame: up to 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 130 non-industry observational studies under Insulin Resistance, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 142. This study's planned 35 months is below that.

Counting every sponsor, half of 133 studies reached it within 53 months; a quarter within 18 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Jan 20, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06793072
Responsible party
Iwona Magdalena Gawron (PhD, MD, Principal Investigator, Jagiellonian University) — Principal investigator
First posted
Jan 27, 2025
Start date
Jan 20, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Iwona Gawron, Ph.D., M.D.
Contact
iwona.gawron@uj.edu.pl
+48 124248570
Robert Jach, Prof., Ph.D., M.D.
Contact
jach@cm-uj.krakow.pl
+48 124248570
Kazimierz Pityński, Prof., Ph.D., M.D.
study chair · Jagiellonian University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion